Journal: Journal of Hematology & Oncology

Article Title: COVID-19 vaccines for patients with cancer: benefits likely outweigh risks

doi: 10.1186/s13045-021-01046-w

Figure Lengend Snippet: Advantages and disadvantages of various types of COVID19 vaccines in development

Article Snippet: Replication incompetent adenoviral vector , AstraZeneca (ChAdOx1 nCoV-19; AZD1222) Johnson & Johnson (Ad26.COV2.S) CanSino Biologics (Ad5-nCoV) Gamaleya (Sputnik V) , Replication-defective, no new viral particles Avoids intact pathogen Mimics natural infection Elicits humoral and cellular immunity , Anti-vector immunity may interfere Lower efficacy if prior anti-vector immunity exists.

Techniques: Plasmid Preparation, Introduce, Produced, Ex Vivo, Infection

Journal: American Journal of Physiology - Heart and Circulatory Physiology

Article Title: Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice

doi: 10.1152/ajpheart.00373.2015

Figure Lengend Snippet: Angiopoietin-1 (Ang-1*) decreases the vascular permeability in the mesenteric vessels of mice treated with rAd-FGF-2 + PPS. FVB/N mice were injected with rAd-FGF-2 alone or in combination with rAd-Ang-1* (5 × 108 pfu/mouse for each adenoviral vector). Seven days later, all mice were injected with PPS (60 mg/kg), anesthetized, and injected retro-orbitally with 100 μl of Evans Blue (EB) dye (5 mg/ml in PBS). The EB injection alone produced a homogeneous bluish staining of the gastrointestinal tract in control mice (B) compared with control mice not injected with EB (A). C: a representative sample of mice treated with PPS plus rAd-FGF-2 demonstrating more significant leakage of EB compared with mice treated with PPS + rAd-FGF-2 + rAd-Ang-1* (D). E: the leakage of the EB dye was quantified in fluid collected from the peritoneal cavity, using arbitrary optical density units, and the results are expressed as means ± SE (n = 3 mice per group; one way ANOVA **P < 0.001 compared with control mice; ##P < 0.001 compared with mice treated with rAd-FGF-2 + PPS). Bars = 0.5 cm.

Article Snippet: We thank Dr. J. Rudge from Regeneron Pharmaceuticals for providing the Ang-1* adenoviral vectors and performing the Ang-1* assays.

Techniques: Permeability, Injection, Plasmid Preparation, Produced, Staining, Control

Journal: American Journal of Physiology - Heart and Circulatory Physiology

Article Title: Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice

doi: 10.1152/ajpheart.00373.2015

Figure Lengend Snippet: Ang-1* increases the survival of mice treated with rAd-FGF-2 + PPS. A: a Kaplan-Meier survival curve. A single dose of PPS (60 mg/kg) was injected 24 h and 7 days after the infection with the corresponding adenoviral (rAd) vectors (n = 15–21 mice per group). Log-rank test comparisons of survival curves: P < 0.001 in mice treated with rAd-Lac-Z + PPS vs. all the other groups. B: the survival of mice with different FGF-2 plasma levels *P < 0.05; **P < 0.0001. C summarizes the number of mice alive or dead at the end of the experiment (rAd-FGF + PPS vs. rAd-Ang-1* +rAd-FGF-2 + PPS; Chi-square test, P < 0.0001; rAd-Lac-Z + PPS vs. rAd-Ang-1* rAd-FGF-2 + PPS, P > 0.05). D: representative pictures of the lethal abdominal bleeding in mice. SI, small intestine; L, liver. Black arrows point to the hemorrhages.

Article Snippet: We thank Dr. J. Rudge from Regeneron Pharmaceuticals for providing the Ang-1* adenoviral vectors and performing the Ang-1* assays.

Techniques: Injection, Infection, Clinical Proteomics

Journal: American Journal of Physiology - Heart and Circulatory Physiology

Article Title: Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice

doi: 10.1152/ajpheart.00373.2015

Figure Lengend Snippet: Coagulation and hematological analysis in blood samples collected from anesthetized mice 7 days after the adenoviral infection, and 1.5 h after the injection of a single dose of PPS (60 mg/kg)

Article Snippet: We thank Dr. J. Rudge from Regeneron Pharmaceuticals for providing the Ang-1* adenoviral vectors and performing the Ang-1* assays.

Techniques: Coagulation, Infection, Injection, Control